The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO GI 2024 | Potential of immunotherapy in MSS metastatic colorectal cancer
David Tougeron, MD, PhD, Poitiers University Hospital, Poitiers, France, highlights the potential of immune checkpoint inhibitors in patients with high immune scores in microsatellite stable (MSS) metastatic colorectal cancer, as demonstrated in the AtezoTRIBE trial (NCT03721653), when combined with chemotherapy. Prognostic biomarkers of immunotherapies range from polymutants to high tumor mutation burden (TMB) in patients. This interview took place at 2024 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Annual Congress in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
